培美曲塞加奈达铂密集化疗联合康莱特治疗肺癌疗效及对患者ERCC1、ALK水平的影响

Effects of Pemetrexed Plus Nedaplatin Intensive Chemotherapy Combined with Kanglaite in the Treatment of Lung Cancer and Its Influence on ERCC1 and ALK Levels

目的:观察培美曲塞加奈达铂密集化疗联合康莱特治疗肺癌的临床疗效,及对患者修复交叉互补组1(ERCC1)、间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)水平的影响。方法:90例肺癌患者随机分为观察组和对照组每组45例,对照组给予培美曲塞加奈达铂密集化疗治疗,观察组在此基础上联合康莱特注射液治疗。观察两组临床疗效和药品不良反应,比较两组患者治疗前后血清ERCC1、ALK水平与免疫功能变化情况。结果:观察组肿瘤控制率为46.67%,显著高于对照组的24.44%(P<0.05)。治疗后,两组患者血清ERCC1水平较前显著升高,ALK突变水平和CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、NK百分率则较前显著下降(P<0.05);而观察组上述指标均明显优于对照组(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:培美曲塞加奈达铂密集化疗联合康莱特治疗肺癌效果显著,能显著改善患者的血清ERCC1水平,下调ALK变异,提高机体免疫功能,且安全性较高。

Objective:To study the effects of pemetrexed plus nedaplatin intensive chemotherapy combined with Kanglaite in the treatment of lung cancer and its influence on ERCC1 and anaplastic lymphoma kinase(ALK)levels.Methods:Totally 90 patients with lung cancer were randomly divided into observation group and control group with 45 patients in each group.The control group was treated with pemetrexed and nedaplatin intensive chemotherapy,and the observation group was treated with Kanglaite injection on the basis of control group.The clinical efficacy and adverse drug reactions were observed in the two groups,and serum ERCC1 and ALK levels and the changes of immune function were compared between the two groups before and after treatment.Results:The tumor control rate of observation group was 46.67%,which was significantly higher than that(24.44%)of control group(P<0.05).After treatment,the serum ERCC1 level in the two groups was significantly increased,while the ALK mutation level and the percentages of CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and NK were significantly decreased(P<0.05).The above indexes in the observation group were significantly better than those in the control group(P<0.05).There was no significant difference in the incidence of ADRs between the two groups(P>0.05).Conclusion:Pemetrexed plus nedaplatin intensive chemotherapy combined with Kanglaite can be used in patients with lung cancer,and after treatment,serum ERCC1 can be up-regulated and ALK mutation down-regulated in patients with lung cancer.